Glenmark Pharmaceuticals Quarterly Results for Trading Insights
In Sept 2025, Glenmark Pharmaceuticals (GLENMARK) reported revenue ₹6,204 Cr and net profit ₹610 Cr — revenue +80.3% YoY. Compare with GLENMARK fair price to assess whether the stock is under or overvalued.
GLENMARK Quarterly Results — Revenue, Profit & EPS Highlights
Glenmark Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore GLENMARK share price history to track price trends across different timeframes.
- Revenue of ₹6,204 Cr in Sept 2025 (+92.0% vs Mar 2025, +80.3% vs Sept 2024)
- Net Profit of ₹610 Cr in Sept 2025 (+15150.0% vs Mar 2025, +71.8% vs Sept 2024)
- EBITDA of ₹1,132 Cr in Sept 2025 (+590.2% vs Mar 2025)
- Operating Margin of 16.0% in Sept 2025 (+11.0pp vs Mar 2025)
- Earnings Per Share of ₹21.63 in Sept 2025 (+13418.8% vs Mar 2025)
Glenmark Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GLENMARK quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6,204 | 3,232 | 3,086 | 3,933 | 3,440 | 92.0% | 80.3% |
| Net Profit (₹ Cr) | 610 | 4 | 47 | 403 | 355 | - | - |
| EBITDA (₹ Cr) | 1,132 | 164 | 79 | 717 | 608 | - | - |
| EPS (₹) | 21.63 | 0.16 | 1.66 | 14.29 | 12.55 | - | - |
| Operating Margin (%) | 16.0% | 5.0% | 2.0% | 17.0% | 17.0% | - | - |
GLENMARK Share Price Trend — 1-Year Movement Across Quarterly Results
Glenmark Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Glenmark Pharmaceuticals screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GLENMARK vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Glenmark Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores